The Impact of Healthcare-Associated Infection on Mortality: Failure in Clinical Recognition Is Related with Inadequate Antibiotic Therapy

Teresa Cardoso1, Orqueida Ribeiro2, Irene Aragão3, Altamiro Costa-Pereira2, António Sarmento4
1 Intensive Care Unit – Unidade de Cuidados Intensivos Polivalente – Hospital Geral de Santo António, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, 2 Department of Health Information and Decision Sciences, Center for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal, 3 Intensive Care Unit – Unidade de Cuidados Intensivos Polivalente – Hospital Geral de Santo António, University of Porto, Porto, Portugal, 4 Department of Infectious Diseases, Hospital de São João, University of Porto, Porto, Portugal

Abstract

Purpose: To understand if clinicians can tell apart patients with healthcare-associated infections (HCAI) from those with community-acquired infections (CAI) and to determine the impact of HCAI in the adequacy of initial antibiotic therapy and hospital mortality.

Methods: One-year prospective cohort study including all consecutive infected patients admitted to a large university tertiary care hospital.

Results: A total of 1035 patients were included in this study. There were 718 patients admitted from the community: 225 (31%) with HCAI and 493 (69%) with CAI. Total microbiologic documentation rate of infection was 68% (n = 703): 56% in CAI, 73% in HCAI and 83% in hospital-acquired infections (HAI). Antibiotic therapy was inadequate in 27% of patients with HCAI vs. 14% of patients with CAI (p < 0.001). Among patients with HCAI, 47% received antibiotic therapy in accordance with international recommendations for treatment of CAI. Antibiotic therapy was inadequate in 36% of patients with HCAI whose treatment followed international recommendations for CAI vs. 19% in the group of HCAI patients whose treatment did not follow these guidelines (p = 0.014). Variables independently associated with inadequate antibiotic therapy were: decreased functional capacity (adjusted OR = 2.24), HCAI (adjusted OR = 2.09) and HAI (adjusted OR = 2.24). Variables independently associated with higher hospital mortality were: age (adjusted OR = 1.05, per year), severe sepsis (adjusted OR = 1.92), septic shock (adjusted OR = 8.13) and inadequate antibiotic therapy (adjusted OR = 1.99).

Conclusions: HCAI was associated with an increased rate of inadequate antibiotic therapy but not with a significant increase in hospital mortality. Clinicians need to be aware of healthcare-associated infections among the group of infected patients arriving from the community since the existing guidelines regarding antibiotic therapy do not apply to this group and they will otherwise receive inadequate antibiotic therapy which will have a negative impact on hospital outcome.

Introduction

According to the 2012 World Health Organization report, infections are among the top three leading causes of death worldwide [1], with community-acquired infections playing a major role.

At the end of the XXth century, there was a significant increase in the healthcare service provided in the outpatient setting. As a consequence, the debate about the need to add a third category named “healthcare-associated infections” [2–4] to the existing dichotomy classification of community- and hospital-acquired infections, arose.

The classification of healthcare-associated infection proposed by Deborah Friedman in 2002 [2], is one of the most widely used in clinical studies. According to her, it is an infection present at the time of hospital admission or within 48 hours of admission, in patients who fulfill any of the following criteria:

- Received intravenous therapy at home, wound care or specialized nursing care through a healthcare agency, family or friends; or, self-administered intravenous medical therapy in the 30 day period before the onset of the infection. Patients whose only home therapy was oxygen use are excluded.

- Received intravenous therapy at home, wound care or specialized nursing care through a healthcare agency, family or friends; or, self-administered intravenous medical therapy in the 30 day period before the onset of the infection. Patients whose only home therapy was oxygen use are excluded.
Attended a hospital or haemodialysis clinic, or having received intravenous chemotherapy in the previous 30 days.

Were hospitalized in an acute care hospital for 2 or more days in the previous 90 days.

Resided in a nursing home or long-term care facility.

Since then, several studies have shown that the microbiologic profiles of healthcare-associated infections differ from those of community-acquired infections [2–4], and that this needs to be taken into account when prescribing first intention antibiotic therapy. If healthcare-associated infection are not recognized as a separate group among infected patients from the community, it might lead to inadequate first intention antibiotic therapy and worsen the prognosis.

The objectives of this study are: to understand if doctors differentiate between patients with healthcare-associated infections and those with community-acquired infections and to determine the impact of healthcare-associated infection in the adequacy of initial antibiotic therapy and hospital mortality.

**Methods**

**Ethics Statement**

This study was approved by the Institutional Review Board of Hospital de Santo António, Oporto Hospital Centre, Portugal, and informed consent was waived due to the observational nature of the study.

**Study Design and Patient Population**

A prospective cohort study was conducted in a 600-bed tertiary care university hospital over the period of 1 year (1st June 2008 to 31st May 2009). All adult infected patients who were admitted to the medical, surgical, nephrology or hematology wards of the hospital or to the intensive care unit (ICU), whose infection fulfilled the CDC criteria [5], were included. Infections were classified as community-acquired infections (CAI), healthcare-associated infections (HCAI) or hospital-acquired (HAI), according to the place of acquisition.

**Definitions**

- **Community-acquired infections** (CAI) were defined as infections detected within 48 hours of hospital admission in patients who did not fit the criteria for a HCAI.

- **Healthcare-associated infections** (HCAI) were defined by the same criteria that Deborah Friedman used for HCAI bloodstream infections [2], regardless of the involved focus of infection. This choice was based on the fact that this definition is widely used in similar studies and is not limited to bloodstream infections, but can also be applied to respiratory and specific pathogene infections [6–11].

- **Hospital-acquired infections** (HAI) were defined as a localized or systemic condition that resulted from an adverse reaction to the presence of an infectious agent(s) or its toxin(s), that occurred within 48 hours or more after hospital admission and that was not incubating at the time of admission [12]. Infections in patients discharged from the hospital within the previous 2-week period were also included in this group.

The comorbidities of patients in the study included immunosuppression (administration of chemotherapy in the 12 months prior to hospital admission, either radiation therapy or administration of 0.2 mg/kg/day prednisolone for at least 3 months prior to hospital admission, administration of 1 mg/kg/day of prednisolone for 1 week in the 3 months prior to hospital admission or infection with human immunodeficiency virus), chronic liver diseases [13], chronic heart failure [13], chronic respiratory diseases [13], haematological diseases [14], cancer [14], diabetes mellitus requiring insulin therapy or oral hypoglycaemic agents before the infection and/or atherosclerosis (defined as a previous history of a transient ischemic attack, stroke, angina, myocardial infarction or peripheral arterial disease).

| Patients' characteristics | TOTAL (n = 1035) | HCAI (n = 225) | CAI (n = 493) | HAI (n = 317) | HCAI vs CAI | HCAI vs HAI |
|--------------------------|-----------------|----------------|--------------|--------------|-------------|-------------|
| Age, mean (SD)           | 65 (20)         | 68 (19)        | 64 (20)      | 64 (19)      | 0.015*      | 0.022*      |
| Male sex, n (%)          | 506 (49)        | 108 (48)       | 236 (48)     | 162 (51)     | 0.974*      | 0.476*      |
|Severity of infection, n (%) | 281 (27)        | 126 (26)       | 86 (27)      |              |             |             |
| Sepsis                   | 364 (35)        | 178 (36)       | 113 (36)     |              |             |             |
| Severe sepsis            | 296 (29)        | 139 (28)       | 87 (27)      |              |             |             |
| Septic shock             | 94 (9)          | 50 (10)        | 31 (10)      |              |             |             |
| Previous comorbidities, n (%) | 671 (65)        | 270 (55)       | 211 (67)     |              | <0.001*     | <0.001*     |
| Karnofsky index<70, (%)  | 319 (31)        | 115 (23)       | 106 (33)     |              | <0.001*     | <0.001*     |
| Hospitalization in the previous year excluding the last 3 months, n (%) | 413 (40) | 199 (43) | 117 (23) | 174 (55) | <0.001*     | 0.027*      |
| Previous antibiotic therapy, n (%) | 367 (36) | 51 (10) | 230 (73) | <0.001* | <0.001* |
| Inadequate antibiotic therapy, n (%) | 148 (21) | 37 (14) | 66 (25) | <0.001* | 0.601* |
| Hospital mortality, n (%) | 138 (13) | 47 (10) | 59 (19) | 0.063* | 0.178* |

CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, SD – Standard deviation. *Pearson Qui-square Test; # T-student test.

doi:10.1371/journal.pone.0058418.t001
The general medical condition was assessed by the Karnofsky index [15]. A score of less than 70 implies that the patient is unable to perform normal activities or do active work.

“Hospitalization in the previous year” excluded patients already included in the group of patients with HCAI; that is, those with hospital admissions in the previous 3 months.

Sepsis and sepsis-related conditions were diagnosed according to the criteria proposed by the ACCP/SCCM [16].

The initial empirical antibiotic treatment was considered “adequate” if the antibiotic prescribed within the first 24 hours matched in vitro susceptibility of a pathogen deemed to be the likely cause of infection and when the dosage and route of administration were appropriate for current medical status (focus and severity of infection); only patients in which the pathogen was microbiologically identified were considered in this analysis.

To evaluate if doctors treated healthcare-associated infections as community-acquired infections, accordance of initial antibiotic therapy to the Infectious Diseases Society of America (IDSA) international recommendations for the treatment of community-acquired respiratory, urinary and intra-abdominal infections was assessed [17–19].

### Statistical Analysis

Continuous variables are described as means and standard deviations (SD). Categorical variables are described with absolute frequencies and percentages. Student T-tests or Mann-Whitney tests were used to compare continuous values. For categorical variables these comparisons were performed using Pearson χ² test.

Variables associated with inadequate antibiotic therapy and hospital mortality were studied using logistic regression. Those with a clear association in the univariate analysis (p-value < 0.1) were considered in the multivariate analysis [20–22].

#### Table 2. Variables associated with inadequate antibiotic therapy using logistic regression.

| Variables                              | Total n = 703 | Inadequate antibiotic therapy n = 148 | Crude OR   | CI 95%        | p-value |
|----------------------------------------|---------------|---------------------------------------|-------------|---------------|---------|
| Age, mean (SD)                         |               |                                       |             |               |         |
| Age, mean (SD)                         | 65 (19)       | 69 (17)                               | 1.02*       | 1.001–1.03-   | 0.063   |
| Sex, n (%)                             |               |                                       |             |               |         |
| Female                                 | 363 (52)      | 75 (51)                               | 1.00        |               |         |
| Male                                   | 340 (48)      | 73 (49)                               | 1.05        | 0.73–1.51     | 0.793   |
| Previous antibiotic therapy, n (%)    |               |                                       |             |               |         |
| No                                     | 414 (59)      | 74 (50)                               | 1.00        |               |         |
| Yes                                    | 289 (41)      | 74 (50)                               | 1.58        | 1.10–2.28     | 0.014   |
| Hospitalization in the previous year (excluding the last 3 months), n (%) |               |                                       |             |               |         |
| No                                     | 389 (62)      | 64 (50)                               | 1.00        |               |         |
| Yes                                    | 241 (38)      | 64 (50)                               | 1.83        | 1.24–2.72     | 0.001   |
| Comorbidities, n (%)                   |               |                                       |             |               |         |
| No                                     | 222 (32)      | 38 (26)                               | 1.00        |               |         |
| Yes                                    | 481 (68)      | 110 (74)                              | 1.44        | 0.95–2.16     | 0.083   |
| Immunosupression, n (%)                |               |                                       |             |               |         |
| No                                     | 529 (75)      | 115 (78)                              | 1.00        |               |         |
| Yes                                    | 174 (25)      | 33 (22)                               | 0.84        | 0.55–1.30     | 0.437   |
| Chronic hepatic disease, n (%)         |               |                                       |             |               |         |
| No                                     | 686 (98)      | 143 (97)                              | 1.00        |               |         |
| Yes                                    | 17 (2)        | 5 (3)                                 | 1.58        | 0.55–4.56     | 0.396   |
| Chronic heart failure, n (%)           |               |                                       |             |               |         |
| No                                     | 653 (93)      | 134 (90)                              | 1.00        |               |         |
| Yes                                    | 50 (7)        | 14 (10)                               | 1.51        | 0.79–2.87     | 0.214   |
| Chronic respiratory disease, n (%)     |               |                                       |             |               |         |
| No                                     | 661 (94)      | 41 (95)                               | 1.00        |               |         |
| Yes                                    | 42 (6)        | 7 (5)                                 | 0.748       | 0.32–1.70     | 0.474   |
| Chronic haematologic disease, n (%)    |               |                                       |             |               |         |
| No                                     | 652 (93)      | 135 (91)                              | 1.00        |               |         |
| Yes                                    | 51 (7)        | 13 (9)                                | 1.31        | 0.70–2.53     | 0.421   |
| Cancer, n (%)                          |               |                                       |             |               |         |
| No                                     | 670 (95)      | 136 (92)                              | 1.00        |               |         |
| Yes                                    | 33 (5)        | 12 (8)                                | 2.24        | 1.08–4.67     | 0.031   |

*Increase in OR per year; SD – standard deviation, OR – Odds ratio; CI95% - 95% confidence interval.

doi:10.1371/journal.pone.0058418.t002
were selected for the multivariable analysis. The results of the multivariable models are expressed as odds ratio (OR) with 95% confidence interval (CI95%) and p-values. The calibration was tested using the Hosmer-Lemeshow goodness-of-fit test. The significance level was defined as p ≤ 0.05.

Data was analyzed using SPSS, version 18 for Windows (Chicago, IL).

Results

During the study period, a total of 3733 patients were admitted to the selected wards (103 beds); 1035 (28%) met the inclusion criteria of infections according to the CDC definitions of infection.

Of all patients included, 493 (48%) were diagnosed with CAI, 225 (22%) with HCAI and 317 (30%) with HAI.

Patients with HCAI were older, with a higher prevalence of previous comorbidities and inability to perform normal activities (Karnofsky index <70) than patients in the other two groups (p ≤ 0.05). They also had higher rate of admissions to hospital in the period between 3 and 12 months prior to the current episode, as well as previous antibiotic administration and inadequate antibiotic therapy, when compared to patients with CAI (p < 0.001) (Table 1).

Total rate of microbiological documentation of infection was 68% (n = 703): 73% (n = 165) among patients with HCAI, 56% (n = 274) among those with CAI and 83% (n = 264) in the group with HAI.

The empirical antibiotic therapy was changed in 92 patients (13%) among those with microbiological documentation of infection (n = 703). The main reason for changing antibiotic therapy was adjustment to microbiology findings: 81% (n = 26) in HCAI vs 83% (n = 20) in CAI vs 89% (n = 32) in HAI. Other reasons for changing antibiotic therapy were a lack of clinical response in 11% (n = 10), side effects in 3% (n = 3) and others in 1% (n = 1).

In HCAI, 27% had received inadequate antibiotic therapy vs. 14% in CAI (p < 0.001). Among patients with microbiologic documented HCAI, 47% (77) received antibiotic therapy according to international recommendations for CAI. Antibiotic therapy was inadequate in 36% of HCAI patients whose treatment followed the international recommendations for CAI vs 19% in the group of HCAI patients whose treatment did not follow CAI treatment guidelines (p = 0.014).

The rate of inadequate antibiotic therapy among the four categories of HCAI was:

- 33% in the group of patients that received intravenous therapy at home, wound care or specialized nursing care through a healthcare agency, family or friends; or, self-administered intravenous medical therapy in the 30 day period before the onset of the infection;

---

| Table 3. Variables associated with inadequate antibiotic therapy using logistic regression. |
|---------------------------------|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| Variables                      | Total n = 703                  | Inadequate antibiotic therapy n = 148 | Crude OR | CI95% | p-value |
| Diabetes, n (%)                |                                |                                |          |      |        |
| No                             | 558 (79)                      | 119 (80)                      | 1.00     |      |        |
| Yes                            | 145 (21)                      | 29 (20)                       | 0.92     | 0.59–1.45 | 0.727       |
| Atherosclerosis, n (%)         |                                |                                |          |      |        |
| No                             | 539 (77)                      | 101 (68)                      | 1.00     |      |        |
| Yes                            | 162 (23)                      | 47 (32)                       | 1.74     | 1.17–2.60 | 0.007       |
| Karnovsky index <70, n (%)     |                                |                                |          |      |        |
| No                             | 479 (68)                      | 80 (54)                       | 1.00     |      |        |
| Yes                            | 224 (32)                      | 68 (46)                       | 2.17     | 1.50–3.16 | <0.001     |
| Type of infection              |                                |                                |          |      |        |
| Community-acquired, n (%)      | 274 (39)                      | 37 (25)                       | 1.00     |      |        |
| Healthcare-associated, n (%)   | 165 (23)                      | 45 (30)                       | 2.40     | 1.48–3.91 | <0.001     |
| Hospital-acquired, n (%)       | 264 (38)                      | 66 (45)                       | 2.14     | 1.37–3.33 | 0.001      |
| Focus of infection             |                                |                                |          |      |        |
| Respiratory, n (%)             | 215 (31)                      | 44 (30)                       | 1.00     |      |        |
| Urinary, n (%)                 | 306 (43)                      | 69 (47)                       | 1.13     | 0.74–1.73 | 0.570      |
| Intra-abdominal, n (%)         | 124 (18)                      | 24 (16)                       | 0.93     | 0.55–1.63 | 0.806      |
| Other, n (%)                   | 58 (8)                        | 11 (7)                        | 0.91     | 0.44–1.90 | 0.801      |
| Severity of infection          |                                |                                |          |      |        |
| Infection, n (%)               | 191 (27)                      | 41 (28)                       | 1.00     |      |        |
| Sepsis, n (%)                  | 238 (34)                      | 53 (36)                       | 1.05     | 0.66–1.66 | 0.842      |
| Severe sepsis, n (%)           | 209 (30)                      | 43 (29)                       | 0.95     | 0.59–1.53 | 0.827      |
| Septic shock, n (%)            | 65 (9)                        | 11 (7)                        | 0.75     | 0.36–1.55 | 0.433      |

OR – Odds ratio; CI95% - 95% confidence interval.
doi:10.1371/journal.pone.0058418.t003

PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e58418
- 21% in the group of patients that attended a hospital or hemodialysis clinic, or received intravenous chemotherapy in the previous 30 days;
- 30% in the group that were hospitalized in an acute care hospital for 2 or more days in the previous 90 days and
- 36% in those that resided in a nursing home or long-term care facility.

Variables significantly and independently associated with inadequate antibiotic therapy were Karnofsky index, 70 [adjusted OR = 2.24 (CI95% = 1.47–4.41)], HCAI [adjusted OR = 2.09 (CI95% = 1.15–3.80)] and HAI [adjusted OR = 2.24 (CI95% = 1.41–3.55)] (Tables 2 and 3).

Variables significantly and independently associated with higher hospital mortality were age [adjusted OR = 1.05 (CI95% = 1.03–1.07), per year], severe sepsis [adjusted OR = 1.92 (CI95% = 1.01–3.63)], septic shock [adjusted OR = 8.13 (CI95% = 3.84–17.23)] and inadequate antibiotic therapy [adjusted OR = 1.99 (CI95% = 1.20–3.30)] (Table 4).

The Hosmer and Lemeshow test did not show evidence of lack of fit in both models (p > 0.1).

**Discussion**

The results of this study show that doctors treat a high proportion (47%) of patients with healthcare-associated infections according to community-acquired infections treatment recommendations, implying that they do not differentiate this sub-group of patients among those with community-acquired infections.

Patients with healthcare-associated infections who were treated according to the international recommendations for community-acquired infections had a higher rate of inadequate antibiotic therapy than those in whom CAI treatment recommendations were not followed. Healthcare-associated infections were independently associated with inadequate antibiotic therapy. Inadequate antibiotic therapy was an independent risk factor for increased hospital mortality.

Decision making regarding antibiotic treatment is unique, no treatment equals its efficacy. In the meta-analysis on the efficacy of adequate antibiotic therapy for sepsis, by Paul et al [20], the pooled OR for all-cause mortality was 1.6, corresponding to a number needed to treat (NNT) of 10 to save one life, higher than aspirin in acute myocardial infarction (NNT = 41), reinforcing the need to get initial antibiotic therapy adequate in severe infection.

The adequate treatment of healthcare-associated infections is primarily dependent on the correct classification in patients that come from the community as CAI or HCAI. Previous studies [2–4] have shown that patients with HCAI have different microbiological profiles than those with CAI, namely a higher rate of multi-drug resistant pathogens [21], suggesting that the existing guidelines for CAI might not be applicable. Clinicians need to be aware of this difference in order to adapt empiric antibiotic therapy for HCAI patients.

There are a large number of epidemiological studies on healthcare-associated infections [3,4,6,7,9,21–23] but the existing
evidence needs to be systematized, in order to make information more profitable. Respiratory infections are the ones most widely addressed and the American Thoracic Society has already published specific recommendations for healthcare-associated pneumonia [24]; nevertheless, the wide-spectrum antibiotic therapy proposed for these patients has turned into a much-debated subject where there is no consensus among clinicians. Additional studies are needed in this area, with thorough microbiological characterization from different settings, before specific recommendations regarding empirical treatment for different focus of HCAI can be made.

HCAI was not found to be an independent risk factor for hospital mortality although the association of HCAI and higher mortality was described in the studies by Kollef et al [3] and Shorr et al [4]. However, none of them perform a multiple logistic regression to allow the statement of HCAI as an independent risk factor, as it was done in the present study.

There are several studies describing the negative impact of initial inadequate antibiotic therapy on mortality [25–32]. The results of the present study are in accordance with previous findings, from different centres and geographical areas, increasing the probability of wide external applicability of the main results. Major strengths of this study are its prospective design with thorough data collection, the use of clear definitions in the protocol, data collection by a single trained doctor and full completion of all protocols with no missing data per item minimizing any information bias. Additionally, all patients completed the follow-up until hospital discharge. The similarity of some results with previous studies suggests an increased external application of the conclusions.

Conclusions
HCAI were associated with an increased rate of inadequate antibiotic therapy, but not with a significant increase in hospital mortality.

Clinicians need to be aware of healthcare-associated infections among the group of infected patients arriving from the community, as the existing guidelines regarding antibiotic therapy do not apply to them. This is essential in order to prevent the associated inadequate antibiotic therapy and its negative impact on hospital outcome.

The development of specific guidelines for this group of infected patients should be considered.

Author Contributions
Conceived and designed the experiments: TC IA AC-P AS. Performed the experiments: TC IA AC-P AS. Analyzed the data: TC OR. Contributed reagents/materials/analysis tools: TC OR. Wrote the paper: TC OR IA AC-P AS.

References
1. WHO (2012) World Health Statistics 2012. In: WHO G, editor. Available from: http://www.who.int/gho/publications/world_health_statistics/EN_WHS2012_Full.pdf. Accessed 12th February 2013.
2. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, et al. (2002) Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137: 791–797.
3. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, et al. (2005) Epidemiology and outcomes of health-care-associated pneumonia, results from a large US database of community-onset pneumonia. Chest 129: 3054–3062.
4. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, et al. (2006) Healthcare-associated bloodstream infection: a distinct entity? Insights from a large US database. Crit Care Med 34: 2580–2593.
5. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections. Am J Infect Control 16: 128–140.
6. Caratara J, Mykietiuk A, Fernandez-Sabé N, Suárez C, Dorca J et al. (2007) Health care-associated pneumonia requiring hospital admission. Arch Intern Med 167: 1393–1399.
7. Valles J, Calbo E, Anoro E, Fontanals D, Xercavins M, et al. (2007) Bloodstream infection in adults: importance of healthcare-associated infections. Journal of infection 56: 27–34.
8. Cheong HS, Kang C, Kwon KT, Heo ST, Wi YM, et al. (2007) Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia. J Antimicrob Chemother 60: 1255–1260.
9. Park HK, Song JU, Um SW, Koh WJ, Suh GY, et al. (2010) Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. Respir Med 104: 179–188.
10. Rello J, Llauján M, Gallego M, Valles J, Belmonte Y, et al. (2010) Why mortality is increased in health-care-associated pneumonia: lessons from Pneumococcal Bacteremic Pneumonia. Chest 137: 1180–1114.
11. Stryjewski ME, Kanafi ZA, Chiu VH, Pappas PA, Harding T, et al. (2009) Staphylococcus aureus bacteremia among patients with health-care-associated fever. Am J Med 122: 201–208.
12. Pop-Vicas AE, D’Aguia EMC (2005) The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 40: 1752–1786.
13. Knauz WA, Draper EA, Wagner DP, Zimmerman JE (1983) APACHE II: a severity of disease classification system. Crit Care Med 13: 818–829.
14. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. Jama 270: 2957–2963.
15. Karnofsky DA, Burchenal JH (1949) "The Clinical Evaluation of Chemotherapeutic Agents in Cancer." In: MacLeod CM, editor. Evaluation of Chemotherapeutic Agents. Columbia: Univ Press. 196.
16. Bour RC, Balk RA, Cerra BF, Dellinger RP, Fein AM, et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644–1655.
17. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, et al. (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2: S27–72.
18. Gupta K, Hooton TM, Naber KG, Wulf B, Golgan R, et al. (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52: e103–120.
19. Solomkin JS, Mazuoki JE, Bradley JS, Rodvold KA, Goldstein EJC, et al. (2010) Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50: 133–164.
20. Paul M, Shani V, Muchtar E, Kariv G, Robenholt K, et al. (2010) Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 54: 4831–4836.
21. Miek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH (2007) Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 51: 3568–3573.
22. Leuz R, Leal JR, Church DL, Gregson DB, Ross T, et al. (2012) The distinct category of healthcare associated bloodstream infections. BMC Infect Dis 12: 85.
23. Aguilar-Duran S, Horcajada JP, Soriñ L, Montero M, Salvador M, et al. (2012) Community-onset healthcare-related urinary tract infections: comparison with community and hospital-acquired urinary tract infections. J Infect 64: 478–483.
24. American Thoracic Society (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388–416.
25. Gomez J, Garcia-Vazquez E, Banos R, Canteras M, Ruiz J, et al. (2007) Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis 26: 239–245.
26. Kollef MH, Sherman G, Ward S, Fraser VF (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115: 426–474.

27. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samura Z, et al. (1998) The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 244: 379–386.

28. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118: 146–155.

29. Bassetti M, Trecarichi EM, Mesini A, Spanu T, Giacobbe DR, et al. (2012) Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect 18: 862–869.

30. Rodriguez-Bano J, Millan AB, Domíguez MA, Borraz G, Gonzalez MP, et al. (2009) Impact of inappropriate empirical therapy for sepsis due to healthcare-associated methicillin-resistant Staphylococcus aureus. J Infect 58: 131–137.

31. Retamar P, Portillo MM, Lopez-Prieto MD, Rodriguez-Lopez F, de Cueto M, et al. (2012) Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 56: 472–478.

32. Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, et al. (2010) Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 65: 2656–2663.